Deals
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
H.E.L. Group Ltd, a global manufacturer of innovative laboratory tools for process optimization, safety and scale-up, announced the appointment of Louise Madden as Chief Executive Officer (CEO).
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc that Amphion has agreed to amend the terms of the Loan Facility with Amphion’s debt provider.
Ergomed plc, a company focused on providing specialised services to the global pharmaceutical industry, announces its unaudited interim results for the six months ended 30 June 2019.
Tacalyx announced that it has successfully secured €7 million in seed funding.
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces its unaudited interim results for the six months ended 30 June 2019.
60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists
Catalyst Pharmaceuticals, Inc., is commenting on trading activity in its common stock and on the current state of its capital resources.
Faron announces its unaudited interim results for the six months ended 30 June 2019.
OncoCyte, a global oncology diagnostics company, recently announced that it will acquire Razor Genomics, which has developed a novel molecular diagnostic test for early-stage non-small cell lung cancer.